Lavine Team

Location and Contact Information

622 West 168th Street
Presbyterian Hospital Building, PH17-105F
New York, NY 10032
United States

Principal Investigators

Nonalcoholic steatohepatitis is the most common chronic liver disease in the United States in both children and adults, responsible for a rapidly increasingly rate of end-stage liver disease and cancer. This problem is coincident with the rapid rise in prevalence of obesity and diabetes. The Lavine team piloted the use of multiple pharmacologic therapies to later test in NIH-funded multicenter randomized controlled trials, including those published in Lancet, New England Journal, and Journal of the American Medical Association. These demonstrated the efficacy and safety of treatment with certain antioxidants or insulin-sensitizing drugs. Our research demonstrated the unique histopathology of fatty liver uniquely found in children, the prevalence in the general population, and the clinico-pathologic correlates associated with disease severity. Our current research investigates the role of receptor hormones regulating gene expression profiles in fatty liver disease, the genetic and epigenetic loci associated with disease severity, and the influence of specific sex hormones on fat and inflammation correlating with age of onset and gender disparity. Our work spans a variety of disciplines that includes experts in radiology, pathology, internal medicine, genetics, endocrinology, and metabolism.

The equivalent of this is foie gras.  You have to force-feed ducks to get fatty liver, but people seem to be able to develop it on their own.

Dr. Joel Lavine on the rapid rise of nonalcoholic fatty liver among American children and adults, New York Times Quotation of the Day, June 14, 2014.

Lab Members

  • Tyree Perez

    Team Coordinator

  • Elena Reynoso, MD

  • Ali Mencin, MD

  • Julia Wattacheril, MD

  • Zach Pitkowsky

    MD Student, Vagelos College of Physicans and Surgeons

  • Zoe Cohen

    MD Student, Vagelos College of Physicans and Surgeons

  • Kelly Naranjo

    Research Coordinator

Select Publications

  • Wattacheril J, Lavine JE*, Chalasani NP, Guo X, Kwon S, Schwimmer J, Molleston J, Loomba R, Brunt EM, Chen YI, Goodarzi M, Taylor KD, Yates KP, Tonascia J, Rotter J. Genome wide associations related to the spectrum of histologic features in nonalcoholic fatty liver disease in Hispanic boys. 2017. J. Pediatr. 190: 100-107. PMID: 28918882

  • Elbel E, Lavine JE*, Downes M, Van Natta M, Yu R, Schwimmer JB, Behling C, Brunt E, Tonascia JT, Evans RM. Hepatic nuclear receptor expression associates with features of histology in pediatric nonalcoholic fatty liver disease. Hepatology Communications. 2018. Accepted.

  • Schwimmer JB, Lavine JE, Wilson LA, Neuschwander-Tetri BA, Xanthakos S, Kohli R, Barlow S, Vos MB, Karpen SJ, Molleston JP, Whitington PF, Rosenthal P, Jain AK, Murray KF, Brunt E, Kleiner DE, Van Natta ML, Clark JM, Tonascia J, Doo E, NASH CRN. In children with nonalcoholic fatty liver disease, cysteamine bitartrate delayed release improves liver enzymes but does not reduce disease activity scores. Gastroenterology. 2016. 151(6): 1141-1154. PMID: 27569726

  • Lavine JE, Schwimmer JB, Van Natta ML, Molleston J, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Unalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR for the Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial. JAMA. 2011. 305(16): 1659-1668. PMID 21521847

  • Patton HM, Yates K, Unalp-Arida A, Behling C, Huang TT, Schwimmer JB, Lavine JE*. Association between metabolic syndrome and liver histology among children and adolescents with nonalcoholic fatty liver disease. Am J Gastroenterol. 2010. 105(9): 2093-2102. PMID 20372110.

  • Sanyal AJ, Chalasani N, Kowdley K, McCullough A, Diehl AM, Bass N, Neuschwander-Tetri B, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt E, Kleiner D, Hoofnagle J, Robuck P, NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. 2010. New Engl J Med. 2010. 362: 1675-1685. PMID 20427778.

  • Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Chalasani N, Dasarthy S, Diehl AM, Hameed B, Kowdley K, McCullough A, Clark J, Tonascia J, Brunt EM, Kleiner DE, Doo E for the NASH CRN. Farnesoid-X nuclear receptor ligand obeticholic acid for non-cirrhotic, nonalcoholic steatohepatitits (FLINT): a multicentre, randomized, placebo-controlled trial. Lancet. 2015. 385(9972): 956-65. PMID 25468160.